Related Experiment Video
Updated: Jun 8, 2025
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
17.4K
[Triple negative breast cancer: Current status and perspectives]
Fanny Le Du1, Emilie Moati2, Pauline Vaflard3
1Département d'oncologie médicale, centre de lutte contre le cancer Eugène-Marquis, Rennes, France; Inserm UMR_S 1242, Oncogenesis Stress Signalling, université de Rennes, Rennes, France.
Bulletin Du Cancer
|November 7, 2024
Summary
Triple negative breast cancer (TNBC) is an aggressive subtype with poor survival. Advances include immunotherapy and targeted therapies, but TNBC remains a significant clinical challenge requiring personalized treatment strategies.
Area of Science:
- Oncology
- Genetics
- Immunology
Context:
- Triple negative breast cancer (TNBC) constitutes 10-15% of breast cancers.
- TNBC is defined by the lack of estrogen/progesterone receptors and HER2 overexpression.
- It exhibits aggressive behavior, high recurrence risk, and less favorable survival rates.
Purpose:
- To review current therapeutic strategies for TNBC.
- To highlight challenges and recent advancements in TNBC management.
- To emphasize the need for personalized approaches due to TNBC's heterogeneity.
Summary:
- Chemotherapy is the primary treatment for TNBC, with neoadjuvant strategies standard in early stages.
- Dose-dense regimens and carboplatin improve response rates; immunotherapy (pembrolizumab) enhances recurrence-free survival.
- Metastatic TNBC treatment utilizes theranostic markers for immunotherapy or PARP inhibitors, with antibody-drug conjugates showing promise.
Impact:
- Recent progress has been made, but TNBC remains a critical clinical challenge.
- Understanding TNBC's biology is crucial for developing effective treatments.
- Personalized therapeutic strategies are essential to improve outcomes for patients with this aggressive cancer.
